Amylyx Pharmaceuticals, Inc. Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc.

AMLX

株式のランク #4349
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
株価
$28.83
時価総額
$3.62B
変化（1日）
5.49%
変化（1年）
87.57%
国
US
取引 Amylyx Pharmaceuticals, Inc. (AMLX)

カテゴリー

Healthcare
Amylyx Pharmaceuticals, Inc.（AMLX）の株式分割履歴
Amylyx Pharmaceuticals, Inc.株（シンボル：AMLX）は合計で0回の株式分割を実施しました。
最新の株式分割はOct 20, 2026に行われました。
Oct 20, 2026より前に購入されたAMLX株は、現在0AMLX株に相当します。
株式分割一覧
年 株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL